Vanessa E Rees1, Jürgen B Bulitta2, Roger L Nation1, Brian T Tsuji3, Fritz Sörgel4, Cornelia B Landersdorfer5. 1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria 3052, Australia. 2. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria 3052, Australia School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA. 3. School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA. 4. IBMP-Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Str. 19, Nürnberg-Heroldsberg, Germany Institute of Pharmacology, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany. 5. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria 3052, Australia School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA cornelia.landersdorfer@monash.edu.
Abstract
OBJECTIVES: For fluoroquinolones, the area under the free plasma concentration-time curve divided by the MIC (fAUC/MIC) best predicts bacterial killing in mice and outcomes in patients. However, it is unknown whether the shape of the antibiotic concentration profile affects resistance emergence. Our objective was to compare killing and resistance between ciprofloxacin concentration profiles with different shapes at the same fAUC/MIC and identify the durations of ciprofloxacin exposure that minimize resistance emergence. METHODS: Static time-kill studies over 24 h using Pseudomonas aeruginosa ATCC 27853 assessed fAUC/MIC of 44 and 132 of ciprofloxacin (MICCIP = 0.25 mg/L) and fAUC/MIC of 22, 44 and 132 of ciprofloxacin plus an efflux pump inhibitor (MICCIP+EPI = 0.031 mg/L) at initial inocula of 10(4), 10(5) and 10(6) cfu/mL. Ciprofloxacin was added at 0 h and rapidly removed at 1, 4, 10, 16 or 24 h. Mutant frequencies and MICs were determined at 24 h. RESULTS: High ciprofloxacin concentrations over 1-10 h yielded more rapid and extensive initial killing compared with 16 and 24 h exposures at the same fAUC/MIC. No resistance emerged for 1-10 h exposures, although regrowth of susceptible bacteria was extensive. Ciprofloxacin exposure over 24 h yielded less regrowth, but ciprofloxacin-resistant bacteria at 5× MIC amplified by over 5 log10 and almost completely replaced the susceptible bacteria by 24 h; MICs increased 4- to 8-fold. Resistance also emerged on 3× MIC, but not 5× MIC, plates when efflux was inhibited. CONCLUSIONS: Pre-existing resistant subpopulations amplified extensively with 24 and 16 h exposures, but not with shorter durations. The shape of the ciprofloxacin concentration profile was critical to minimize resistance emergence.
OBJECTIVES: For fluoroquinolones, the area under the free plasma concentration-time curve divided by the MIC (fAUC/MIC) best predicts bacterial killing in mice and outcomes in patients. However, it is unknown whether the shape of the antibiotic concentration profile affects resistance emergence. Our objective was to compare killing and resistance between ciprofloxacin concentration profiles with different shapes at the same fAUC/MIC and identify the durations of ciprofloxacin exposure that minimize resistance emergence. METHODS: Static time-kill studies over 24 h using Pseudomonas aeruginosa ATCC 27853 assessed fAUC/MIC of 44 and 132 of ciprofloxacin (MICCIP = 0.25 mg/L) and fAUC/MIC of 22, 44 and 132 of ciprofloxacin plus an efflux pump inhibitor (MICCIP+EPI = 0.031 mg/L) at initial inocula of 10(4), 10(5) and 10(6) cfu/mL. Ciprofloxacin was added at 0 h and rapidly removed at 1, 4, 10, 16 or 24 h. Mutant frequencies and MICs were determined at 24 h. RESULTS: High ciprofloxacin concentrations over 1-10 h yielded more rapid and extensive initial killing compared with 16 and 24 h exposures at the same fAUC/MIC. No resistance emerged for 1-10 h exposures, although regrowth of susceptible bacteria was extensive. Ciprofloxacin exposure over 24 h yielded less regrowth, but ciprofloxacin-resistant bacteria at 5× MIC amplified by over 5 log10 and almost completely replaced the susceptible bacteria by 24 h; MICs increased 4- to 8-fold. Resistance also emerged on 3× MIC, but not 5× MIC, plates when efflux was inhibited. CONCLUSIONS: Pre-existing resistant subpopulations amplified extensively with 24 and 16 h exposures, but not with shorter durations. The shape of the ciprofloxacin concentration profile was critical to minimize resistance emergence.
Authors: M Cristina Vazquez Guillamet; Rodrigo Vazquez; Jonas Noe; Scott T Micek; Victoria J Fraser; Marin H Kollef Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079
Authors: Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Brian T Tsuji; Craig R Rayner; Roger L Nation; Cornelia B Landersdorfer Journal: J Antimicrob Chemother Date: 2016-08-11 Impact factor: 5.790
Authors: Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Jürgen B Bulitta; Veronika Wirth; Antonio Oliver; John D Boyce; Anton Y Peleg; Roger L Nation; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2018-10-24 Impact factor: 5.191
Authors: Karin Kipper; Charlotte I S Barker; Joseph F Standing; Mike Sharland; Atholl Johnston Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Joseph F Standing; Brian J Anderson; Nicholas H G Holford; Irja Lutsar; Tuuli Metsvaht Journal: Clin Pharmacokinet Date: 2015-12 Impact factor: 6.447
Authors: J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver Journal: Rev Esp Quimioter Date: 2018-02-23 Impact factor: 1.553
Authors: Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer Journal: Pharmaceutics Date: 2019-09-12 Impact factor: 6.321